Czechia has approved the medical use of psilocybin, a key shift in drug policy that allows regulated therapeutic applications in clinical settings. This commentary places the reform within international trends, drawing on the publication "How to Regulate Psychedelics" and qualitative findings from a ketamine-assisted therapy program in the Czech Destigmatizing the Therapeutic Use of Psychedelics in Psychiatry project. It examines regulation of non-clinical psychedelic use and highlights legal ambiguity around the offence of "spreading toxicomania." The authors advocate for a rational, evidence-based regulatory approach, arguing that medicalization alone is incomplete without clear pathways for non-clinical use to ensure safety and legal clarity.
Psychedelic-assisted therapy (PAT) may help people stop committing crimes by promoting identity transformation and personal meaning-making. Drawing on psychedelic science and desistance-focused criminological theories, the paper argues that when administered ethically, psychedelics can enhance self-reflection, emotional processing, and inner insight—mechanisms that support sustained behavioral change. Because many justice-involved individuals experience trauma, depression, and substance dependence, PAT could be a particularly relevant intervention. The paper recommends community-based, post-release settings rather than correctional institutions for PAT delivery. It acknowledges that causal evidence on recidivism outcomes is lacking and calls for carefully designed pilot studies. Using Czechia as a policy context, it offers a roadmap for research and implementation, positioning PAT as a complementary component within broader rehabilitation and reintegration strategies.